Wedbush reiterates Telix Pharmaceuticals stock rating at $22 target

Wedbush reiterated an Outperform rating and $22 price target for Telix Pharmaceuticals (TLX) after its Capital Markets Day. The company reaffirmed 2026 revenue guidance of $950M-$970M and expects $1.5B in 2027 revenue, including $300M from ITM. TLX reported 1H 2026 revenue of AUD 477M, up 22% YoY, with net profit of AUD 38M. The company has three FDA-approved imaging products and aims for six by this time next year.

Original reporting
Published Nov 4, 2026, 11:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TLX
Bullish
medium confidence
Mentioned
$TLX
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TLXBullishMed
01

Why it matters

The upgraded rating and higher target provide a fresh catalyst for TLX, likely prompting short‑term buying pressure.

02

Market read

Analyst upgrade with a substantial price target increase creates a near‑term trading opportunity for TLX.

03

What to watch

Potential regulatory delays or trial setbacks could temper the upside.

Relevance 6/10Novelty 5/10Timing: today

Background

Wedbush's reiteration follows Telix's Capital Markets Day where it outlined revenue guidance and pipeline progress.

Company-level read

Ticker impact

$TLXBullishMedium confidence
Context

Wedbush reiterated an Outperform rating and raised its price target to $22, up from prior levels, indicating fresh analyst optimism.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The new $22 target represents a 144% upside from the current $9.03 price, providing a clear catalyst for short‑term buying.

Market effects

Positive sentiment may spill over to other precision‑medicine and imaging biotech stocks.

Limited to US‑listed biotech sector.

Modest; primarily affects TLX and peers.

Counterpoint

The target may be overly optimistic given the company's cash burn and reliance on upcoming trial data.

Key entities

  • Telix Pharmaceuticals Ltd

    US‑listed biotech focused on precision‑medicine imaging.

  • Wedbush Securities

    Equity research firm that issued the rating and target.

Related articles

$TLXMed

Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push

Telix Pharmaceuticals (NASDAQ:TLX) aims for $1.5B in revenue next year, driven by its prostate cancer imaging and therapy programs. Key studies include BiPASS for PSMA-PET imaging and OPTIMAL-PSMA for TLX597-Tx therapy. The company also advances programs for brain and kidney cancer, with FDA approvals expected for PIXCLARA and a decision pending for Zircaix. Telix expects six approved products by next year, subject to regulatory approvals.

$TLXHighAI 9/10

Telix Reports Third Quarter 2026 Financial Performance

Telix Pharmaceuticals reported Q3 2026 revenue of $245M, up 19% YoY, driven by strong demand for its PSMA products. Precision Medicine revenue grew 30% to $201M. The FDA approved Pixclara for glioma imaging, and the company completed BiPASS study enrollment. Telix also announced a merger with ITM, expecting FY 2026 revenue to exceed $1B.

$TLXMed

A scarce radioactive material studied for cancer treatment could be made in the U.S.

Telix Pharmaceuticals and Ekalia (a joint venture between IBA and Framatome) are collaborating to establish U.S. production of astatine-211 (211At), a rare radioisotope for cancer treatment. The partnership will use IBA's cyclotron technology and Telix's U.S. radiopharmacy infrastructure. Telix aims to advance its alpha therapy pipeline, including TLX102-Tx for glioblastoma, and support third-party research.